ClinicalTrials.gg
CompletedNCT01606254Updated Jun 5, 2013Results posted

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

A Phase 2 interventional study of Paliperidone palmitate in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-06-05.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
89th of 115
56 · median 178
Started
2007
with 14 others
Phase 2
5 of 115
none open now
Registered
78th of 115
by date
Lead sponsor
7 of 115
Janssen Pharmaceutical K.K.

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 89th largest by enrollment, is one of 15 that started in 2007, is one of 5 in phase 2, and was the 78th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Read the detailed description

This is a multicenter (when more than one hospital or medical school team work on a medical research study), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), parallel-group (Each group of participants will be treated at the same time), comparison study to assess the pharmacokinetics and safety of paliperidone palmitate (study medication) in participants with schizophrenia. The study comprises a 64-day Treatment period and a 155-day Follow-up period. The participants will be randomly assigned to one of the four study groups. The study medication will be administered on Days 1, 8, 36 and 64. Pharmacokinetics of the study medication will be assessed as primary outcome. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone Palmitate
  • JNS010
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Participants who have been diagnosed with schizophrenia in accordance with the diagnostic criteria of 4th edition (DSM-IV)
  • Participants may be inpatients or outpatients
  • Participants who have been taking an oral antipsychotic medication for at least 28 days before the date of
  • Participants with a Positive and Negative Syndrome Scale (PANSS) score of less than or equal to 4 (moderate) at screening
  • Participants who have taken risperidone by the start of treatment and the record can be confirmed Exclusion Criteria
  • Participants who have been diagnosed with a mental disease other than schizophrenia in accordance with the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)
  • Participants who have been diagnosed with substance-related disorders (except nicotine and caffeine dependence)
  • Participants with complicated parkinson's disease (a progressive disorder of the central nervous system, seen usually in older persons, in which there is muscle weakness, trembling and sweating)
  • Participants with a complication of or with a history of convulsive disease such as epilepsy (seizure disorder)
  • Participants with a complication of or with a history of cerebro-vascular accident (stroke), neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness) or physical exhaustion associated with the state of dehydration (lose of water and minerals in the body) or malnutrition
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Paliperidone palmitate 50 mg

    Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.

    Drug: Paliperidone palmitate

  • Experimental
    Paliperidone palmitate 100 mg

    Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.

    Drug: Paliperidone palmitate

  • Experimental
    Paliperidone palmitate 150 mg

    Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.

    Drug: Paliperidone palmitate

  • Experimental
    Paliperidone palmitate 150/ 50 mg

    Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.

    Drug: Paliperidone palmitate

Interventions

  • Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.

    Also known as: JNS010

06

What researchers measure

Primary outcomes

  1. Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8

    The pre-dose plasma concentration (Cpredose) at Day 8 is defined as the plasma concentration obtained before a dose is given on Day 8. The mean Cpredose at Day 8 was measured in nanogram per milliliter (ng/ml).

    Time frame: Day 8

  2. Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 36

    The Cpredose at Day 36 is defined as the plasma concentration obtained before a dose is given on Day 36. The mean Cpredose at Day 36 was measured in ng/ml.

    Time frame: Day 36

  3. Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 64

    The Cpredose at Day 64 is defined as the plasma paliperidone concentration obtained before a dose is given on Day 64. The mean Cpredose at Day 64 was measured in ng/ml.

    Time frame: Day 64

  4. Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 92

    The Cpredose at Day 92 is defined as the plasma paliperidone concentration obtained after the treatment interval of the study drug (that is 4 weeks) passed after the final dose (Day 92). The mean Cpredose at Day 92 was measured in ng/ml.

    Time frame: Day 92

  5. Maximum Observed Plasma Concentration (Cmax) of Paliperidone

    The Cmax is defined as maximum observed analyte concentration.

    Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Paliperidone

    The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

    Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal

  7. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

    The AUCtau is a measure of the plasma paliperidone concentration from time zero to end of dosing interval. It is used to characterize drug absorption.

    Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal

  8. Plasma Paliperidone Concentration at Steady State (Css av)

    The Css av is defined as value of average analyte concentration at steady-state (after 4 Intramuscular Injections of Paliperidone Palmitate).

    Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal

  9. Paliperidone Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal

  10. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 8

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 8

  11. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 22

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 22

  12. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 50

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 50

  13. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 78

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 78

  14. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 92

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 92

  15. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 120

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 120

  16. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 162

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 162

  17. Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 218

    The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

    Time frame: Day 218

Secondary outcomes

  1. Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).

    Time frame: Baseline, Day 8, 22, 50, 78 and 92

  2. Number of Participants With Clinical Global Impression Severity (CGI-S) Score

    The CGI-S rating scale is a 7 point (1-absent, 2-minimal, 3-mild, 4-moderate, 5-moderate severe, 6-severe, 7-extreme) global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: Baseline, Day 8, 22, 50, 78 and 92

07

Results

Posted Apr 18, 2013

Participant flow

Participant flow — Overall Study
MilestonePaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Started14141414
Completed12101411
Not completed2403
Withdrew: Withdrawal by subject1302
Withdrew: Adverse event1101

Outcome measures

PrimaryPaliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8

The pre-dose plasma concentration (Cpredose) at Day 8 is defined as the plasma concentration obtained before a dose is given on Day 8. The mean Cpredose at Day 8 was measured in nanogram per milliliter (ng/ml).

Time frame:
Day 8
Reported as:
Mean · ng/ml
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8
ng/mlPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 85.85 ± 4.477.28 ± 4.9228.4 ± 29.212.1 ± 7.46
PrimaryPaliperidone Pre-dose Plasma Concentration (Cpredose) at Day 36

The Cpredose at Day 36 is defined as the plasma concentration obtained before a dose is given on Day 36. The mean Cpredose at Day 36 was measured in ng/ml.

Time frame:
Day 36
Reported as:
Mean · ng/ml
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 36
ng/mlPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 366.77 ± 3.7514.5 ± 5.7623.4 ± 18.619.5 ± 16.1
PrimaryPaliperidone Pre-dose Plasma Concentration (Cpredose) at Day 64

The Cpredose at Day 64 is defined as the plasma paliperidone concentration obtained before a dose is given on Day 64. The mean Cpredose at Day 64 was measured in ng/ml.

Time frame:
Day 64
Reported as:
Mean · ng/ml
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 64
ng/mlPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 646.86 ± 3.3115.1 ± 9.1622.9 ± 16.314.3 ± 9.01
PrimaryPaliperidone Pre-dose Plasma Concentration (Cpredose) at Day 92

The Cpredose at Day 92 is defined as the plasma paliperidone concentration obtained after the treatment interval of the study drug (that is 4 weeks) passed after the final dose (Day 92). The mean Cpredose at Day 92 was measured in ng/ml.

Time frame:
Day 92
Reported as:
Mean · ng/ml
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 92
ng/mlPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 928.41 ± 4.5115.2 ± 6.2125.4 ± 16.813.5 ± 6.38
PrimaryMaximum Observed Plasma Concentration (Cmax) of Paliperidone

The Cmax is defined as maximum observed analyte concentration.

Time frame:
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Reported as:
Mean · ng/ml
Maximum Observed Plasma Concentration (Cmax) of Paliperidone
ng/mlPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Maximum Observed Plasma Concentration (Cmax) of Paliperidone13.7 ± 7.5233.5 ± 19.843.1 ± 30.321.6 ± 12.9
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Paliperidone

The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

Time frame:
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Reported as:
Median · Days
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Paliperidone
DaysPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Paliperidone10.99 (1.99 to 21.01)7.89 (5.97 to 21.81)7.50 (2.93 to 27.01)3.82 (0.71 to 7.07)
PrimaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

The AUCtau is a measure of the plasma paliperidone concentration from time zero to end of dosing interval. It is used to characterize drug absorption.

Time frame:
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Reported as:
Mean · nanogram*hour per milliliter
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
nanogram*hour per milliliterPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)7081 ± 358115898 ± 753521853 ± 1553411109 ± 5390
PrimaryPlasma Paliperidone Concentration at Steady State (Css av)

The Css av is defined as value of average analyte concentration at steady-state (after 4 Intramuscular Injections of Paliperidone Palmitate).

Time frame:
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Reported as:
Mean · ng/ml
Plasma Paliperidone Concentration at Steady State (Css av)
ng/mlPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Plasma Paliperidone Concentration at Steady State (Css av)10.7 ± 5.4223.9 ± 11.432.8 ± 23.116.7 ± 8.28
PrimaryPaliperidone Plasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Reported as:
Mean · Days
Paliperidone Plasma Decay Half-Life (t1/2)
DaysPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Paliperidone Plasma Decay Half-Life (t1/2)68.1 ± 48.058.5 ± 29.195.5 ± 98.8104.4 ± 97.1
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 8

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 8
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 8
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None6966
Very mild8567
Mild0021
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 22

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 22
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 22
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None7766
Very mild7678
Mild0010
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 50

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 50
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 50
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None11786
Very mild3556
Mild0010
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 78

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 78
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 78
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None9886
Very mild4455
Mild0010
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 92

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 92
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 92
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None7775
Very mild6566
Mild0010
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 120

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 120
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 120
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None9666
Very mild4565
Mild0020
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 162

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 162
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 162
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None9767
Very mild3464
Mild0020
PrimaryNumber of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 218

The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).

Time frame:
Day 218
Reported as:
Number · Participants
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 218
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
None9766
Very mild3475
Mild0010
SecondaryPositive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).

Time frame:
Baseline, Day 8, 22, 50, 78 and 92
Reported as:
Mean · units on a scale
Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scalePaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Baseline (n = 14, 14, 14, 14)61.9 ± 12.3960.7 ± 17.2860.4 ± 16.7663.9 ± 15.58
Day 8 (n = 14, 14, 13, 14)60.0 ± 13.8559.6 ± 19.4457.8 ± 17.2162.6 ± 15.33
Day 22 (n = 14, 14, 14, 14)56.8 ± 13.1958.1 ± 19.5957.1 ± 16.1060.4 ± 13.15
Day 50 (n = 14, 14, 14, 14)57.9 ± 17.4960.0 ± 20.4756.5 ± 15.0462.8 ± 13.89
Day 78 (n = 14, 14, 14, 14)56.4 ± 17.0760.4 ± 20.0557.2 ± 18.5559.9 ± 13.03
Day 92 (n = 14, 14, 14, 14)56.4 ± 17.7960.2 ± 20.3857.4 ± 17.8360.6 ± 13.52
SecondaryNumber of Participants With Clinical Global Impression Severity (CGI-S) Score

The CGI-S rating scale is a 7 point (1-absent, 2-minimal, 3-mild, 4-moderate, 5-moderate severe, 6-severe, 7-extreme) global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
Baseline, Day 8, 22, 50, 78 and 92
Reported as:
Number · Participants
Number of Participants With Clinical Global Impression Severity (CGI-S) Score
ParticipantsPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Baseline, Minimal (n=14,14,14,14)3431
Baseline, Mild (n=14,14,14,14)86108
Baseline, Moderate (n=14,14,14,14)3315
Baseline, Moderate severe (n=14,14,14,14)0100
Day 8, Minimal (n=14,14,13,14)3331
Day 8, Mild (n=14,14,13,14)87910
Day 8, Moderate (n=14,14,13,14)3213
Day 8, Moderate severe (n=14,14,13,14)0200
Day 22, Minimal (n=14,14,14,14)4542
Day 22, Mild (n=14,14,14,14)8599
Day 22, Moderate (n=14,14,14,14)2313
Day 22, Moderate severe (n=14,14,14,14)0100
Day 50, Minimal (n=14,14,14,14)5530
Day 50, Mild (n=14,14,14,14)741013
Day 50, Moderate (n=14,14,14,14)1310
Day 50, Moderate severe (n=14,14,14,14)1201
Day 78, Minimal (n=14,14,14,14)6551
Day 78, Mild (n=14,14,14,14)64812
Day 78, Moderate (n=14,14,14,14)1301
Day 78, Moderate severe (n=14,14,14,14)1210
Day 92, Minimal (n=14,14,14,14)5451
Day 92, Mild(n=14,14,14,14)75811
Day 92, Moderate (n=14,14,14,14)1302
Day 92, Moderate severe (n=14,14,14,14)1210

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Palmitate 50 mg—1/14 (7.1%)14/14 (100%)
Paliperidone Palmitate 100 mg—0/14 (0%)14/14 (100%)
Paliperidone Palmitate 150 mg—2/14 (14.3%)14/14 (100%)
Paliperidone Palmitate 150/ 50 mg—3/14 (21.4%)14/14 (100%)
Most frequent serious events
Most frequent serious events
EventPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Psychiatric symptomPsychiatric disorders0/140/140/142/14
SchizophreniaPsychiatric disorders1/140/140/140/14
Suicide attemptPsychiatric disorders0/140/141/140/14
ConvulsionNervous system disorders0/140/140/141/14
Grand mal convulsionNervous system disorders0/140/141/140/14
Neuroleptic malignant syndromeNervous system disorders0/140/141/140/14
HypothermiaGeneral disorders0/140/141/140/14
Most frequent other events
Showing 10 of 124
Most frequent other events
EventPaliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mg
Blood prolactin increasedInvestigations11/149/1413/1410/14
Psychiatric symptomPsychiatric disorders5/146/143/143/14
NasopharyngitisInfections and infestations5/144/144/144/14
InsomniaPsychiatric disorders3/143/144/141/14
Weight increasedInvestigations4/142/143/142/14
HypertensionVascular disorders3/140/140/140/14
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders1/141/142/143/14
Back painMusculoskeletal and connective tissue disorders1/140/141/143/14
Injection site painGeneral disorders1/141/143/142/14
Weight decreasedInvestigations3/143/141/142/14

Baseline characteristics

Age Continuous
Age Continuous(Years)Paliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mgTotal
Mean46.4 ± 13.845.2 ± 11.148.7 ± 11.849.4 ± 12.147.4 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mgTotal
Female253616
Male12911840
Number of Participants with Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score
Number of Participants with Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score(Participant)Paliperidone Palmitate 50 mgPaliperidone Palmitate 100 mgPaliperidone Palmitate 150 mgPaliperidone Palmitate 150/ 50 mgTotal
None885526
Very mild668929
Mild00101
08

Study locations

1 site
  • Ichikawa, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2012
First posted
May 25, 2012
Start
Jan 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Apr 18, 2013
Last update
Jun 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01606254
Responsible party
Sponsor
First posted
May 25, 2012
Start date
Jan 2007
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Apr 18, 2013
Last update
Jun 5, 2013

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion